B

    bioAffinity Technologies, Inc. (BIAF)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $4.56
    -0.31 (-6.37%)

    Market Cap: $2.88M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(7/14)
    Avg Surprise
    -13.35%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 7
    		$-0.64N/AN/ABeat-276.5%
    Mar 26
    Reported May 8
    		$-0.81N/AN/ABeat-406.3%
    Dec 25
    Reported Mar 13
    		$-10.46$-11.44+8.56%Beat-5405.9%
    Sep 25
    Reported Nov 14
    		$-4.74$-2.70-75.56%Miss-2862.5%
    Jun 25
    Reported Aug 14
    		$-0.17$-0.10-70.00%Miss+10.5%
    Mar 25
    Reported May 15
    		$-0.16$-0.17+5.88%Beat+37.7%
    Dec 24
    Reported Mar 31
    		$-0.19$-0.14-35.71%Miss-
    Sep 24
    Reported Nov 14
    		$-0.16$-0.15-6.67%Miss+38.5%
    Jun 24
    Reported Aug 14
    		$-0.19$-0.17-11.76%Miss+5.0%
    Mar 24
    Reported Apr 1
    		$-0.26$-0.20-28.35%Miss-42.6%
    Dec 23
    Reported Mar 5
    		$0.00N/A+100.00%Beat+100.0%
    Sep 23
    Reported Nov 14
    		$-0.26$-0.15-73.33%Miss+77.8%
    Jun 23
    Reported Aug 14
    		$-0.20$-0.20+0.00%Beat-566.7%
    Mar 23
    Reported May 15
    		$-0.18$-0.18+0.00%Beat+62.5%
    Dec 22
    Reported Mar 31
    		$-0.19$-0.19+0.00%Beat-
    Sep 22
    Reported Nov 14
    		$-1.17$-1.17+0.00%Beat-
    Jun 22
    Reported Sep 2
    		$-0.03N/AN/ABeat-
    Mar 22
    Reported Jun 16
    		$-0.48N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.02EV/EBITDA-0.21x
    Price/FCF-2.06xFCF Yield-48.53%
    Profitability
    Profit Margin-257.30%Operating Margin-220.80%
    ROE-1860.00%ROIC-396.26%
    Financial Health
    Debt/Equity0.02xInterest Coverage-338.30x
    Current Ratio1.44xQuick Ratio1.41x
    Trading Statistics
    Beta-1.05Avg Volume8.73M
    52-Week High$202.5052-Week Low$4.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.58
    SMA 20$6.35
    SMA 50$9.20
    SMA 200$22.51
    EMA 10$5.47
    EMA 20$6.47
    EMA 50$10.44
    EMA 200$33.78

    MACD

    Line: -1.49Signal: -1.57Hist: 0.08

    ADX

    ADX: 55.9+DI: 5.6-DI: 1.6

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down52.0
    PSAR$1.45

    Bollinger Bands

    Upper Band$8.63
    Lower Band$4.07
    %B Position7176%(Upper)
    Band Width0.11

    RSI (14-Day)

    Oversold
    22.9

    Momentum Oscillators

    Stoch %K74.8
    Stoch %D77.3
    Williams %R-29.7
    ROC (10d)-22.4%
    Momentum-1.32
    CCI (20d)81.9
    MFI (14d)95.0

    Volatility Measures

    ATR (14d)$5.39(118.2%)
    StdDev (20d)1.14
    Hist Vol122.1%(High)

    Volume Flow

    VWAP$4.70
    OBV1.6B
    AD Line3349.4B
    CMF (20d)106.640

    Volume Metrics

    Avg Vol (20d)9.2M
    Vol Ratio0.0x(Low)
    VWMA (20d)$7.04

    Pivot Points

    R3$5.37
    R2$5.27
    R1$5.07
    Pivot Point$4.97
    S1$4.77
    S2$4.67
    S3$4.47

    Advanced Oscillators

    TSI-49.01
    Ultimate Osc82.5
    KST-416.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M$2.35M$2.40M$2.41M$2.21M$298,484
    Cost of Revenue$0$0$1.29M$0$0$0$1.72M$0$0$0$1.66M$0
    Gross Profit$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M$2.35M$2.40M$2.41M$2.21M$298,484
    Operating Expenses$4.85M$4.97M$4.73M$3.74M$3.79M$4.48M$5.15M$4.32M$4.49M$4.35M$4.56M$2.59M
    R&D$837,460$683,747$668,813$473,900$440,651$505,739$518,186$368,202$453,895$442,599$528,169$436,798
    SG&A$3.95M$4.17M$3.04M$2.21M$3.23M$3.82M$2.92M$2.36M$2.47M$2.19M$2.21M$2.02M
    Operating Income$-3,334,864$-3,616,976$-3,136,963$-2,292,846$-2,515,560$-2,627,139$-2,946,553$-1,973,864$-2,087,798$-1,945,230$-2,342,404$-2,294,504
    Interest Income$3,358$10,026$19,730$1,088$2,025$542$4,069$2,228$5,186$6,127$12,160$27,193
    Interest Expense$11,688$14,722$13,069$5,358$10,460$15,485$25,045$21,631$22,249$23,550$25,325$8,785
    Income Before Tax$-3,366,082$-3,630,610$-3,134,285$-5,047,902$-4,031,803$-2,651,722$-2,966,897$-1,998,281$-2,104,860$-1,958,143$-2,370,871$-2,288,590
    Income Tax Expense$0$0$3,181$3,182$28,984$8,695$0$2,559$5,419$3,672$2,293$2,294
    Net Income$-3,366,082$-3,630,610$-3,137,466$-5,051,084$-4,060,787$-2,660,417$-2,966,897$-2,000,840$-2,110,279$-1,961,815$-2,373,164$-2,290,884
    EBITDA$-3,296,196$-3,511,396$-3,017,287$-4,930,272$-3,910,139$-2,482,191$-2,792,289$-1,827,580$-1,936,727$-1,791,083$-2,208,919$-2,249,429
    EBIT$-3,357,752$-3,625,914$-3,140,946$-5,043,632$-4,023,368$-2,636,779$-2,945,921$-1,978,878$-2,087,797$-1,940,720$-2,357,706$-2,306,998
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIAF

    News

    bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance

    bioAffinity Technologies is exploring a new application for its CyPath Lung test, aiming to use it for surveillance in lung cancer survivors post-treatment. This expansion could broaden the test's commercial opportunities beyond initial detection, addressing the challenge of monitoring recurrence or new cancers after curative-intent treatment. While previous trials showed high sensitivity for detection, the company will need to validate its performance specifically for post-treatment surveillance to establish its clinical and commercial potential.

    Yahoo Finance•9/1/26•
    Somewhat-Bullish

    bioAffinity Technologies (BIAF) Earnings Date and Reports 2026 $BIAF

    bioAffinity Technologies (BIAF) reported Q2 2026 earnings, beating EPS estimates with -$9.60 against a -$31.50 consensus, though revenue of $1.51 million fell short of the $1.70 million estimate. The company's next earnings report is anticipated on November 18, 2026. The article provides a detailed historical earnings table and information on upcoming financial events for BIAF.

    MarketBeat•8/28/26•
    Somewhat-Bullish

    Price to earnings forward of bioAffinity Technologies, Inc. – BOATS:BIAFW

    This article provides financial information for bioAffinity Technologies, Inc. (BIAFW) on the TradingView platform, specifically focusing on its price-to-earnings forward metric. It indicates that the market was closed at the time of viewing and no trades were recorded for the stock.

    TradingView•8/21/26•
    Neutral

    BioAffinity Technologies To Carry Out 1-for-15 Reverse Stock Split On August 24th, 2026

    BioAffinity Technologies announced a 1-for-15 reverse stock split of its common stock, effective August 24th, 2026. This action is intended to increase the per-share trading price to meet Nasdaq's minimum bid price requirement. The company's shares will begin trading on a split-adjusted basis under the new CUSIP number 076594204.

    Moomoo•8/21/26•
    Neutral

    bioAffinity Technologies executes 1-for-15 reverse stock split

    bioAffinity Technologies (NASDAQ:BIAF) has announced a 1-for-15 reverse stock split, effective at the opening of trading on the Nasdaq Capital Market. This action, approved by stockholders in April 2026, aims to bring the company into compliance with Nasdaq's minimum bid price requirement. Following the split, approximately 592,373 shares of common stock will be issued and outstanding.

    Investing.com•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About BIAF

    Does BIAF pay dividends?
    bioAffinity Technologies, Inc. (BIAF) does not currently pay a regular dividend.
    What is BIAF's market cap?
    bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $2.88M with a current stock price of $4.56.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In